Advanced Imaging for Pulmonary Fibrosis

Description

The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.

Conditions

Pulmonary Fibrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.

Advanced Imaging for Pulmonary Fibrosis

Advanced Imaging for Pulmonary Fibrosis

Condition
Pulmonary Fibrosis
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.
  • 2. ILD diagnosis within 5 years of Visit 1.
  • 3. On stable dose immunosuppression treatment (with prednisone, mycophenolate mofetil, and/or rituximab) for at least 3 months.
  • 4. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on HRCT performed within 1 year to or at Visit 1.
  • 5. FVC of \>/= 45% and DLCO \>/= 25% predicted on PFTs performed at Visit 1.
  • 1. Current or prior exposure to FDA approved anti-fibrotic therapy.
  • 2. Extent of emphysema greater than extent of fibrosis.
  • 3. Pregnancy or plans to become pregnant at baseline or during follow-up.
  • 4. Contraindications to MRI.
  • 5. Contraindications to receiving gadolinium-based contrast agents.
  • 6. Research-related radiation exposure exceeds 50 mSv in the prior year.
  • 7. Estimated glomerular filtration rate (eGFR) \< 30 mL/min (only for individuals with a history of chronic kidney disease).
  • 8. Clinically significant PH defined by use of pulmonary vasodilatory therapy.
  • 9. Respiratory infection within the prior 6 weeks.
  • 10. Smoking of any kind within the prior 6 months.

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Peter Caravan,

Sydney Montesi, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2028-12-31